Xcout Intel
Camurus
Camurus is an international pharmaceutical company that develops and provides innovative, long-acting treatments for patients with severe and chronic conditions. The company focuses on therapeutic areas including the central nervous system, rare diseases, endocrinology, oncology, and supportive care.
Subscribe to see Camurus’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Camurus at a glance
Camurus is a pharmaceuticals (drug delivery) company headquartered in Sweden. Xcout tracks 8 named people at Camurus, including Fredrik Tiberg (President & Chief Executive Officer).
Camurus leadership
- Fredrik TibergPresident & Chief Executive Officer
- Per Olof WallströmChairman
- Elisabeth BjorkBoard member
- Erika Söderberg JohnssonBoard Member
- Hege HellstromBoard member
- Jakob LindbergBoard member
2 more named people on record for Camurus, with roles, board committees and tenure — see the full roster →
Camurus competitors
A few of Camurus's closest competitors — see the full list of competitors and alternatives →
Ipsen is a global biopharmaceutical company that researches, develops, and commercializes innovative medicines. It primarily serves patients suffering from conditions in the fields of oncology, rare diseases, and neuroscience.
Orexo AB is a pharmaceutical company that specializes in developing innovative drug delivery technologies, notably its powder-based AmorphOX platform. The company advances proprietary and partnered pharmaceutical products, including treatments, vaccines, and nasal delivery formulations, serving patients and healthcare partners globally.
Grünenthal is a global pharmaceutical company that researches, develops, and commercializes innovative treatments and medicines with a primary focus on pain management and related diseases. Operating as a science-based business, the company serves patients worldwide by delivering therapies for conditions such as chronic pain, rare diseases, and neurobiological indications.
Purpose Pharma International AB is a European pharmaceutical company headquartered in Stockholm, Sweden. The firm is dedicated to giving people with rare diseases a better quality of life.
Mendus is a pharmaceutical company based in Sweden and the Netherlands that is dedicated to changing the course of cancer treatment by addressing tumor recurrence.
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.
Get Camurus's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Camurus in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access